- Home
- DNTH vs CHDN Comparison
DNTH vs CHDN Comparison
Compare DNTH & CHDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNTH | CHDN |
|---|---|---|
| Founded | 2015 | 1928 |
| Country | United States | United States |
| Employees | N/A | 9000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.5B |
| IPO Year | 2018 | 1995 |
Fundamental Metrics
Financial Performance| Metric | DNTH | CHDN |
|---|---|---|
| Price | $111.10 | $93.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | $121.00 | ★ $138.44 |
| AVG Volume (30 Days) | 718.6K | ★ 1.1M |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.43% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 5.49 |
| Revenue | $2,036,000.00 | ★ $1,809,800,000.00 |
| Revenue This Year | N/A | $5.75 |
| Revenue Next Year | $29.48 | $3.52 |
| P/E Ratio | ★ N/A | $16.96 |
| Revenue Growth | N/A | ★ 13.31 |
| 52 Week Low | $22.81 | $79.40 |
| 52 Week High | $117.88 | $118.35 |
Technical Indicators
Market Signals| Indicator | DNTH | CHDN |
|---|---|---|
| Relative Strength Index (RSI) | 54.51 | 64.79 |
| Support Level | $79.27 | $86.54 |
| Resistance Level | $114.55 | $95.36 |
| Average True Range (ATR) | 5.11 | 2.63 |
| MACD | -0.55 | 0.71 |
| Stochastic Oscillator | 42.67 | 98.58 |
Price Performance
Historical ComparisonAbout DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
About CHDN Churchill Downs Incorporated
Churchill Downs Inc is a gaming entertainment, online wagering, and racing company. It operates through three business segments: Live and Historical Racing, Wagering Services, and Gaming. The Live and Historical Racing segment includes live and historical pari-mutuel racing. The Wagering Services segment includes the revenue and expenses from pari-mutuel wagers through TwinSpires, companies retail and online sports betting business and Gaming segment includes revenue and expenses for the casino properties and associated racetracks that support the casino license. The Gaming segment generates revenue and expenses from slot machines, video lottery terminals, video poker, HRMs, ancillary food and beverage services, hotel services, commission on pari-mutuel wagering, and racing events.